CPX-351 improved overall survival among older patients with myelodysplastic-related AML who undergo hematopoietic transplantation. CPX-351 treatment resulted in improved overall survival (OS) among ...
AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...
LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating agents LYT-200 demonstrates clinical benefit as a single ...
Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper infrastructure, while treatment decisions are based on intensive vs ...
A 1,563‑sample chromatin atlas reveals 16 epigenomic subgroups of AML, redefining disease classification, prognosis, and therapeutic vulnerabilities.
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) Phase 1b dataset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results